Anesiva Announces First Quarter 2008 Financi... (mpany's progress and future outlook. Int...)

Anesiva Announces First Quarter 2008 Financial Results

Date:5/8/2008

mpany's progress and future outlook. Interested parties can listen to the live conference call by dialing 866-616-3642 (international dial: 706-643-3817) or by logging on to http://www.anesiva.com and going to the Investor Information page. For those unable to participate via the Internet, a replay will be available for seven days after the call by dialing 800-642-1687 (international dial: 706-645-9291) and giving the following pass code: 45132379. The webcast will be available until the company's next quarterly financial results conference call.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. In clinical trials, the most common adverse reactions to Zingo were redness (erythema), red dots (petechiae) and swelling (edema). The second product in Anesiva's pipeline, Adlea(TM), reduces pain after only a single administration for weeks to months based on mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may,
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook

Post Your Comments:

(Date:6/19/2013)... Washington (PRWEB) June 18, 2013 A ... complex materials, costs and other trends will highlight technical ... Monterey, California this fall. In its 33rd year, the ... includes an exhibition of key suppliers, approximately 100 technical ... SPIE, the international society for optics and photonics ...

(Date:6/18/2013)... 18, 2013 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its preliminary unaudited financial results for the fourth ... March 31, 2013. Fourth Quarter of ... quarter of fiscal 2013 increased by 33.3% to RMB133.0 ...

(Date:6/18/2013)... The human skin is the largest organ, ... human body part. Similar to the liver, or heart, the ... repair and grow. Recent reports from the mankatofreepress.com explained how ... as important as other life supporting organs. The article suggests ... cell reproduction, increase the appearance of skin, and fight off ...

(Date:6/18/2013)... 2013 regulated information — Global biopharmaceutical company UCB, ... announced the launch of a new Pledge campaign for ... The Pledge empowers the millions of Americans ... a personal commitment to demand more: greater understanding of ... and additional partial-onset seizure control. More information is available ...

[0] ‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology [0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin [0] Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy

... 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ... his research group at The Institute of Cancer ... testing combination treatment schedules,of reovirus and radiation in ... in,vivo. The paper, entitled "Enhanced In vitro and ...

... 2008) -- A University of Waterloo physics and astronomy ... in Science Magazine, shows how some solids behave like ... James Forrest and then-graduate student Zahra Fakhraai, take a ... substances using nanoscale technology. , They explore the properties ...

... 1 MannKind Corporation,(Nasdaq: MNKD ), focused on ... today that it will present at,the Merrill Lynch Global ... at 1:40 PM ET at the Grand Hyatt Hotel ... link to the live web cast of the,presentation in ...

Cached Biology Technology:Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy 2 UW paper in Science shows how some solids mimic liquids on nanoscale 2

Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy UW paper in Science shows how some solids mimic liquids on nanoscale MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference

(Date:6/18/2013)... the United Kingdom, the Energy Department,s National Renewable ... have recently published a paper describing a novel ... Limnoria quadripunctata , commonly known as the gribble. ... exhibit a relatively unique ability to produce their ... break down the biomass they eat. New biomass-degrading ...

(Date:6/18/2013)... Research Council, Laboratory of Molecular Biology, has been ... Young Investigator Award. Torrent is being recognized for ... algorithm to predict antimicrobial regions in proteins. Luis ... now applying this algorithm to interrogate full genomes ... with very appealing results." , Torrent obtained ...

(Date:6/18/2013)... 18, 2013 The herbal extract of a yellow-flowered ... to increase the lifespan of fruit fly populations by ... researchers. , But it,s how Rhodiola ... that grabbed the attention of study leaders Mahtab Jafari ... works in a manner completely unrelated to dietary restriction ...

Breaking Biology News(10 mins):Novel enzyme from tiny gribble could prove a boon for biofuels research 2 The American Society for Microbiology honors Marc Torrent 2 Herbal extract boosts fruit fly lifespan by nearly 25 percent, UCI study finds 2

[0] Novel enzyme from tiny gribble could prove a boon for biofuels research [0] The American Society for Microbiology honors Marc Torrent [0] Herbal extract boosts fruit fly lifespan by nearly 25 percent, UCI study finds

... In nature, ultraviolet radiation from sunlight is not the ... and females who choose to lay their eggs in the ... amphibian species out of harm,s way most of the time, ... of the long-toed salamander received lethal doses of UV across ...

... Researchers from the p53 Laboratory of Singapore,s Agency for ... makes feasible a unique method of cancer treatment. Their work, ... Differentiation today , offers new insight on how to ... genome, , to more effectively kill cancer cells while sparing ...

... 2010) - A technique pioneered in the Tissue Engineering ... Edward V. Zegarelli Professor of Dental Medicine at Columbia ... to a three-dimensional scaffold infused with growth factor, holding ... in as soon as nine weeks once implanted. ...

Cached Biology News:Ultraviolet radiation not culprit killing amphibians, research shows 2 Ultraviolet radiation not culprit killing amphibians, research shows 3 Singapore scientists exploit knowledge of p53 for increasing specificity of cancer treatments 2 Technique yields potential biological substitute for dental implants 2

Ultraviolet radiation not culprit killing amphibians, research shows Singapore scientists exploit knowledge of p53 for increasing specificity of cancer treatments Technique yields potential biological substitute for dental implants

Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...

C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...

...

AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...

Biology Products:

Mouse Anti-C2 Monoclonal Antibody, Unconjugated, Clone 050-04 from Abcam Rabbit Anti-C/EBPalpha Polyclonal Antibody, Unconjugated from Cell Signaling Technology QCapture PRO from QImaging Mouse Anti-Human AADAC Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents